share_log

Recursion Pharmaceuticals | 144: Notice of proposed sale of securities pursuant to Rule 144

Recursion Pharmaceuticals | 144: Notice of proposed sale of securities pursuant to Rule 144

Recursion Pharmaceuticals | 144:擬議出售證券
美股SEC公告 ·  08/14 04:27
牛牛AI助理已提取核心訊息
Recursion Pharmaceuticals, Inc. officer Secora Michael is set to sell 15,000 Class A shares of the company, with an aggregate market value of $95,182.98, on 08/13/2024. These shares were originally acquired on 06/14/2023 through a stock option exercise, purchased from the issuer with cash. This planned sale follows a three-month period where a total of 60,000 shares were sold by the officer, generating gross proceeds of $497,232.86. The notice of the upcoming sale was filed on the same date as the planned sale, with the sale instructions having been adopted earlier on 03/01/2024.
Recursion Pharmaceuticals, Inc. officer Secora Michael is set to sell 15,000 Class A shares of the company, with an aggregate market value of $95,182.98, on 08/13/2024. These shares were originally acquired on 06/14/2023 through a stock option exercise, purchased from the issuer with cash. This planned sale follows a three-month period where a total of 60,000 shares were sold by the officer, generating gross proceeds of $497,232.86. The notice of the upcoming sale was filed on the same date as the planned sale, with the sale instructions having been adopted earlier on 03/01/2024.
Recursion Pharmaceuticals,Inc.高級管理人員Secora Michael計劃以總市值爲95,182.98美元的價格出售15,000股公司A類股份,於2024年08/13日進行交易。這些股票最初是於2023年06/14日通過股票期權行使購買的,用現金從發行人購買。此次計劃出售是在股東代表大會批准並已經採納的指示的基礎上,距離該高管已經售出60,000股股票,收入價值爲497,232.86美元,過去三個月內剛剛完成。本次股票出售計劃的相關公告和規定已在同一日期進行備案,並於較早的2024年03/01日通過。
Recursion Pharmaceuticals,Inc.高級管理人員Secora Michael計劃以總市值爲95,182.98美元的價格出售15,000股公司A類股份,於2024年08/13日進行交易。這些股票最初是於2023年06/14日通過股票期權行使購買的,用現金從發行人購買。此次計劃出售是在股東代表大會批准並已經採納的指示的基礎上,距離該高管已經售出60,000股股票,收入價值爲497,232.86美元,過去三個月內剛剛完成。本次股票出售計劃的相關公告和規定已在同一日期進行備案,並於較早的2024年03/01日通過。

譯文內容由第三人軟體翻譯。


牛牛AI助手部分由第三方人工智慧模型基於資訊內容自動產生,只对除中国内地以外的地区提供。


以上內容僅用作資訊或教育之目的,不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。